Safety of baricitinib in vaccinated patients with severe and critical COVID-19 sub study of the randomised Bari-SolidAct trial.
Viermyr HK, Tonby K, Ponzi E, Trouillet-Assant S, Poissy J, Arribas JR, Dyon-Tafani V, Bouscambert-Duchamp M, Assoumou L, Halvorsen B, Tekin NB, Diallo A, De Gastines L, Munthe LA, Murphy SL, Ueland T, Michelsen AE, Lund-Johansen F, Aukrust P, Mootien J, Dervieux B, Zerbib Y, Richard JC, Prével R, Malvy D, Timsit JF, Peiffer-Smadja N, Roux D, Piroth L, Ait-Oufella H, Vieira C, Dalgard O, Heggelund L, Müller KE, Møller JH, Kildal AB, Skogen V, Aballi S, Sjøberg Øgaard JD, Dyrhol-Riise AM, Tveita A, Alirezaylavasani A, Costagliola D, Yazdanpanah Y, Olsen IC, Dahl TB, Kared H, Holten AR, Trøseid M.
Viermyr HK, et al. Among authors: muller ke.
EBioMedicine. 2024 Dec 27;111:105511. doi: 10.1016/j.ebiom.2024.105511. Online ahead of print.
EBioMedicine. 2024.
PMID: 39731852
Free article.